熱門資訊> 正文
AnaptysBio在溃疡性结肠炎的主要资产的中期试验中遭遇挫折
2025-11-10 22:56
- AnaptysBio (ANAB) on Monday announced a failure in a Phase 2 trial for its lead candidate rosnilimab in ulcerative colitis, an inflammatory bowel disorder affecting the large intestine and rectum.
- Citing 12-week data, AnaptysBio (ANAB) said the study did not meet the primary endpoint or key secondary endpoints of clinical response and clinical remission, even though rosnilimab was safe and well-tolerated among trial subjects.
- The global trial was designed to evaluate the T cell depleter in moderate-to-severe ulcerative colitis, with its primary endpoint being the mean change from baseline in modified Mayo Score ((mMS)).
- Concurrently, the company disclosed that results won’t support further development of rosnilimab in UC, and as a result, it will not advance the trial any further, generating $10M in savings.
More on AnaptysBio
- AnaptysBio, Inc. (ANAB) ANB033 (CD122 antagonist) Virtual Investor Event - Slideshow
- AnaptysBio, Inc. (ANAB) ANB033 (CD122 antagonist) Virtual Investor Event Transcript
- AnaptysBio, Inc. (ANAB) (ANAB) Strategic Separation To Maximize Shareholder Value Presentation - Slideshow
- AnaptysBio splits operations into two companies
- Seeking Alpha’s Quant Rating on AnaptysBio
推薦文章
資金覆盤 | 北水迴流抄底！淨買入港股超128億港元，搶籌阿里、騰訊、中芯國際
「大空頭」清倉，巴菲特瘋狂囤積現金！當前美股泡沫有多少？
一周財經日曆 | 下周必看！全球股王英偉達將揭曉財報，小鵬、小米、拼多多也輪番登場
新股暗盤 | "新能源材料龍頭"中偉新材跌約1.5%，預計該股將於11月17日正式掛牌上市
全文|B站Q3業績會實錄：B站有國內最好的AI創作者及用户
華盛早報 | 美聯儲放鷹，美股全線大跌！騰訊、京東財報超預期，B站扭虧為盈
美股機會日報 | 阿里巴巴擬改版「千問」對標ChatGPT！思科盤前大漲7%，業績超預期並上調指引
「木頭姐」買入逾2500萬美元阿里巴巴股票，繼續減持特斯拉
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
